middle.news
How Is AFT Pharmaceuticals Driving 33% Revenue Growth and R&D Breakthroughs?
7:40am on Thursday 20th of November, 2025 AEDT
•
Pharmaceuticals
Read Story
How Is AFT Pharmaceuticals Driving 33% Revenue Growth and R&D Breakthroughs?
7:40am on Thursday 20th of November, 2025 AEDT
Key Points
33% revenue growth to $114.9 million in 1H FY26
Positive EBITDA of $6.6 million and net profit of $2.7 million
Strong Australian market performance and recovery in Asia and international hubs
Progress in late-stage R&D including intravenous iron and antibiotic eyedrops
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Aft Pharmaceuticals (ASX:AFP)
OPEN ARTICLE